Giant Cell Tumor of Bone: Oncological and Functional Results of Long-term Follow-up

Yoshinao Oda, Hiromasa Miura, Masazumi Tsuneyoshi, Yukihide Iwamoto

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Background: Giant cell tumor (GCT) of bone is a rare and unpredictable lesion. Its standard treatment has ranged from surgical curettage to wide resection and varying oncological and functional results have been reported. Methods: A retrospective review of 47 patients (17 males and 30 females) with GCT of bone was performed to evaluate the oncological and functional results. The patients were followed up for at least 5 years. The average age of the patients was 32 years (range 15-66 years). The tumor sites were distal femur in 15 cases, proximal tibia in 10, distal radius in five, spinal column in four, proximal femur in three, proximal humerus in three, proximal fibula in two, pelvis in two and others in three. Enneking's surgical stages were Stage 1 in three, Stage 2 in 34 and Stage 3 in 10 cases. In these 47 patients, 80 surgical procedures were performed. Results: The rate of local recurrence was 75% in the 28 patients undergoing intralesional excision, 50% in those receiving excision and curettage and 0% in those receiving wide resection. Although there was no statistical significance, surgical stages tended to be correlated with the local recurrence rate (Stage 1, 0%; Stage 2, 53%; Stage 3, 70%). Functional evaluation was performed according to the most recent system of the Musculoskeletal Tumor Society. Functional results of the patients with extremity tumors were 28.2 (average) in those undergoing intralesional excision, 30 (average) in those receiving excision and curettage and 27.1 (average) in those receiving wide resection. Functional results were significantly correlated with the initial surgical stages (Stage 1, 30; Stage 2, 27.5; Stage 3, 24.4; Kruskal-Wallis test, P = 0.016). Conclusions: To preserve good function of the extremities and avoid local recurrence, we consider that intralesional excision with adjunctive therapy such as phenol cauterization should be employed for the treatment of benign GCT of bone.

Original languageEnglish
Pages (from-to)323-328
Number of pages6
JournalJapanese journal of clinical oncology
Volume28
Issue number5
DOIs
Publication statusPublished - Jan 1 1998

Fingerprint

Giant Cell Tumor of Bone
Curettage
Recurrence
Femur
Extremities
Cautery
Musculoskeletal System
Neoplasms
Fibula
Humerus
Phenol
Pelvis
Tibia
Spine
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Giant Cell Tumor of Bone : Oncological and Functional Results of Long-term Follow-up. / Oda, Yoshinao; Miura, Hiromasa; Tsuneyoshi, Masazumi; Iwamoto, Yukihide.

In: Japanese journal of clinical oncology, Vol. 28, No. 5, 01.01.1998, p. 323-328.

Research output: Contribution to journalArticle

Oda, Yoshinao ; Miura, Hiromasa ; Tsuneyoshi, Masazumi ; Iwamoto, Yukihide. / Giant Cell Tumor of Bone : Oncological and Functional Results of Long-term Follow-up. In: Japanese journal of clinical oncology. 1998 ; Vol. 28, No. 5. pp. 323-328.
@article{911b31d1efbd41d5a811fc53b5fd8e45,
title = "Giant Cell Tumor of Bone: Oncological and Functional Results of Long-term Follow-up",
abstract = "Background: Giant cell tumor (GCT) of bone is a rare and unpredictable lesion. Its standard treatment has ranged from surgical curettage to wide resection and varying oncological and functional results have been reported. Methods: A retrospective review of 47 patients (17 males and 30 females) with GCT of bone was performed to evaluate the oncological and functional results. The patients were followed up for at least 5 years. The average age of the patients was 32 years (range 15-66 years). The tumor sites were distal femur in 15 cases, proximal tibia in 10, distal radius in five, spinal column in four, proximal femur in three, proximal humerus in three, proximal fibula in two, pelvis in two and others in three. Enneking's surgical stages were Stage 1 in three, Stage 2 in 34 and Stage 3 in 10 cases. In these 47 patients, 80 surgical procedures were performed. Results: The rate of local recurrence was 75{\%} in the 28 patients undergoing intralesional excision, 50{\%} in those receiving excision and curettage and 0{\%} in those receiving wide resection. Although there was no statistical significance, surgical stages tended to be correlated with the local recurrence rate (Stage 1, 0{\%}; Stage 2, 53{\%}; Stage 3, 70{\%}). Functional evaluation was performed according to the most recent system of the Musculoskeletal Tumor Society. Functional results of the patients with extremity tumors were 28.2 (average) in those undergoing intralesional excision, 30 (average) in those receiving excision and curettage and 27.1 (average) in those receiving wide resection. Functional results were significantly correlated with the initial surgical stages (Stage 1, 30; Stage 2, 27.5; Stage 3, 24.4; Kruskal-Wallis test, P = 0.016). Conclusions: To preserve good function of the extremities and avoid local recurrence, we consider that intralesional excision with adjunctive therapy such as phenol cauterization should be employed for the treatment of benign GCT of bone.",
author = "Yoshinao Oda and Hiromasa Miura and Masazumi Tsuneyoshi and Yukihide Iwamoto",
year = "1998",
month = "1",
day = "1",
doi = "10.1093/jjco/28.5.323",
language = "English",
volume = "28",
pages = "323--328",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Giant Cell Tumor of Bone

T2 - Oncological and Functional Results of Long-term Follow-up

AU - Oda, Yoshinao

AU - Miura, Hiromasa

AU - Tsuneyoshi, Masazumi

AU - Iwamoto, Yukihide

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Background: Giant cell tumor (GCT) of bone is a rare and unpredictable lesion. Its standard treatment has ranged from surgical curettage to wide resection and varying oncological and functional results have been reported. Methods: A retrospective review of 47 patients (17 males and 30 females) with GCT of bone was performed to evaluate the oncological and functional results. The patients were followed up for at least 5 years. The average age of the patients was 32 years (range 15-66 years). The tumor sites were distal femur in 15 cases, proximal tibia in 10, distal radius in five, spinal column in four, proximal femur in three, proximal humerus in three, proximal fibula in two, pelvis in two and others in three. Enneking's surgical stages were Stage 1 in three, Stage 2 in 34 and Stage 3 in 10 cases. In these 47 patients, 80 surgical procedures were performed. Results: The rate of local recurrence was 75% in the 28 patients undergoing intralesional excision, 50% in those receiving excision and curettage and 0% in those receiving wide resection. Although there was no statistical significance, surgical stages tended to be correlated with the local recurrence rate (Stage 1, 0%; Stage 2, 53%; Stage 3, 70%). Functional evaluation was performed according to the most recent system of the Musculoskeletal Tumor Society. Functional results of the patients with extremity tumors were 28.2 (average) in those undergoing intralesional excision, 30 (average) in those receiving excision and curettage and 27.1 (average) in those receiving wide resection. Functional results were significantly correlated with the initial surgical stages (Stage 1, 30; Stage 2, 27.5; Stage 3, 24.4; Kruskal-Wallis test, P = 0.016). Conclusions: To preserve good function of the extremities and avoid local recurrence, we consider that intralesional excision with adjunctive therapy such as phenol cauterization should be employed for the treatment of benign GCT of bone.

AB - Background: Giant cell tumor (GCT) of bone is a rare and unpredictable lesion. Its standard treatment has ranged from surgical curettage to wide resection and varying oncological and functional results have been reported. Methods: A retrospective review of 47 patients (17 males and 30 females) with GCT of bone was performed to evaluate the oncological and functional results. The patients were followed up for at least 5 years. The average age of the patients was 32 years (range 15-66 years). The tumor sites were distal femur in 15 cases, proximal tibia in 10, distal radius in five, spinal column in four, proximal femur in three, proximal humerus in three, proximal fibula in two, pelvis in two and others in three. Enneking's surgical stages were Stage 1 in three, Stage 2 in 34 and Stage 3 in 10 cases. In these 47 patients, 80 surgical procedures were performed. Results: The rate of local recurrence was 75% in the 28 patients undergoing intralesional excision, 50% in those receiving excision and curettage and 0% in those receiving wide resection. Although there was no statistical significance, surgical stages tended to be correlated with the local recurrence rate (Stage 1, 0%; Stage 2, 53%; Stage 3, 70%). Functional evaluation was performed according to the most recent system of the Musculoskeletal Tumor Society. Functional results of the patients with extremity tumors were 28.2 (average) in those undergoing intralesional excision, 30 (average) in those receiving excision and curettage and 27.1 (average) in those receiving wide resection. Functional results were significantly correlated with the initial surgical stages (Stage 1, 30; Stage 2, 27.5; Stage 3, 24.4; Kruskal-Wallis test, P = 0.016). Conclusions: To preserve good function of the extremities and avoid local recurrence, we consider that intralesional excision with adjunctive therapy such as phenol cauterization should be employed for the treatment of benign GCT of bone.

UR - http://www.scopus.com/inward/record.url?scp=0032062665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032062665&partnerID=8YFLogxK

U2 - 10.1093/jjco/28.5.323

DO - 10.1093/jjco/28.5.323

M3 - Article

C2 - 9703860

AN - SCOPUS:0032062665

VL - 28

SP - 323

EP - 328

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 5

ER -